Vor Biopharma, Inc. (VOR)
NASDAQ:VOR
Want to see VOR full AI Analyst Report?
VOR Stock Chart & Stats
$16.59
<$0.01(<0.01%)
At close: 4:00 PM EST
$16.59
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$3.62 - $65.80
Previous CloseN/A
Volume424.02K
Average Volume (3M)839.65K
Market Cap
$740.18M
Enterprise Value-$64.33M
Total Cash (Recent Filing)$491.52M
Total Debt (Recent Filing)$2.94M
Price to Earnings (P/E)―
Beta4.63
Next Earnings
Aug 06, 2026EPS Estimate
-0.7Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-575.83
Shares Outstanding54,185,880
10 Day Avg. Volume783,207
30 Day Avg. Volume839,653
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.90
Enterprise Value/Market Cap-0.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.30K
Enterprise Value/Ebitda0.06
Forecast
1Y Price Target
$33.80Price Target Upside103.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-5.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Engineered HSC PlatformVor’s engineered donor-derived HSC approach is a platform that can protect healthy cells while enabling targeted agents to eliminate malignant cells. That platform nature supports durable clinical partnerships, modular application across indications, and potential long-term competitive differentiation.
Low Absolute LeverageVery low absolute debt reduces near-term default risk and preserves strategic flexibility for R&D and partnerships. For a pre-commercial biotech, modest debt levels mean the company can prioritize clinical investment without immediate debt servicing strain.
Committed Financing To Fund TrialsThe $75M private placement materially extends runway to fund clinical programs and business development. Structural funding reduces immediate dilution-driven financing urgency and supports multi-quarter execution of trials and partner-building activities.
Bears Say
Pre-revenue ProfileBeing pre-revenue means the company lacks internal cash generation and must rely on capital markets or partners to fund development. This structural funding dependence increases execution risk and lengthens time until sustainable profits.
Materially Widening LossesRapidly expanding net losses have eroded retained capital and driven equity negative. Persistently large operating deficits constrain management choices, raise the need for repeated financings, and can force reprioritization of programs over time.
Heavy Negative Free Cash FlowSustained large negative free cash flow signals chronic cash burn for operations and trials. Structurally, this necessitates continued external funding, increases dilution risk, and limits the company’s ability to scale or sustain long multi-program development without partners.
Vor Biopharma News
VOR FAQ
What was Vor Biopharma, Inc.’s price range in the past 12 months?
Vor Biopharma, Inc. lowest stock price was $3.62 and its highest was $65.80 in the past 12 months.
What is Vor Biopharma, Inc.’s market cap?
Vor Biopharma, Inc.’s market cap is $740.18M.
When is Vor Biopharma, Inc.’s upcoming earnings report date?
Vor Biopharma, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 63 days.
How were Vor Biopharma, Inc.’s earnings last quarter?
Vor Biopharma, Inc. released its earnings results on May 07, 2026. The company reported -$5.11 earnings per share for the quarter, missing the consensus estimate of -$0.781 by -$4.329.
Is Vor Biopharma, Inc. overvalued?
According to Wall Street analysts Vor Biopharma, Inc.’s price is currently Undervalued.
Does Vor Biopharma, Inc. pay dividends?
Vor Biopharma, Inc. does not currently pay dividends.
What is Vor Biopharma, Inc.’s EPS estimate?
Vor Biopharma, Inc.’s EPS estimate is -0.7.
How many shares outstanding does Vor Biopharma, Inc. have?
Vor Biopharma, Inc. has 54,185,880 shares outstanding.
What happened to Vor Biopharma, Inc.’s price movement after its last earnings report?
Vor Biopharma, Inc. reported an EPS of -$5.11 in its last earnings report, missing expectations of -$0.781. Following the earnings report the stock price went up 1.132%.
Which hedge fund is a major shareholder of Vor Biopharma, Inc.?
Currently, no hedge funds are holding shares in VOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vor Biopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.80 (103.74% Upside)
$33.80 (103.74% Upside)
Blogger Sentiment
Bullish
VOR Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $49.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 7.1%
Last 30 Days ▼ 7.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
203.24%
12-Months-Change
Fundamentals
Return on Equity
87.31%
Trailing 12-Months
Asset Growth
363.58%
Trailing 12-Months
Company Description
Vor Biopharma, Inc.
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
VOR Stock 12 Month Forecast
Average Price Target
$33.80
▲(103.74% Upside)
Technical Analysis
Codexis
―
Black Diamond Therapeutics
―
Atea Pharmaceuticals
―
Caribou Biosciences
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
8.32% Insiders
6.21% Mutual Funds
57.07% Other Institutional Investors
23.53% Public Companies and
Individual Investors